$560,000.00 in Sales Expected for Kadmon Holdings Inc (KDMN) This Quarter
Equities research analysts expect that Kadmon Holdings Inc (NYSE:KDMN) will report $560,000.00 in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Kadmon’s earnings. The lowest sales estimate is $150,000.00 and the highest is $1.04 million. Kadmon reported sales of $2.28 million in the same quarter last year, which would suggest a negative year over year growth rate of 75.4%. The business is scheduled to issue its next earnings results on Thursday, November 8th.
On average, analysts expect that Kadmon will report full-year sales of $2.45 million for the current fiscal year, with estimates ranging from $1.04 million to $3.60 million. For the next financial year, analysts anticipate that the firm will report sales of $41.21 million per share, with estimates ranging from $600,000.00 to $115.64 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that cover Kadmon.
Kadmon (NYSE:KDMN) last posted its earnings results on Thursday, August 9th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of ($0.26) by $0.50. The firm had revenue of $0.36 million during the quarter, compared to the consensus estimate of $0.90 million.
Institutional investors have recently bought and sold shares of the business. AE Wealth Management LLC raised its position in shares of Kadmon by 3.7% during the second quarter. AE Wealth Management LLC now owns 529,212 shares of the company’s stock worth $2,112,000 after acquiring an additional 18,750 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Kadmon during the first quarter worth about $106,000. Voya Investment Management LLC bought a new position in shares of Kadmon during the second quarter worth about $101,000. Metropolitan Life Insurance Co. NY bought a new position in shares of Kadmon during the second quarter worth about $105,000. Finally, Citadel Advisors LLC raised its position in shares of Kadmon by 181.3% during the first quarter. Citadel Advisors LLC now owns 49,500 shares of the company’s stock worth $210,000 after acquiring an additional 31,906 shares during the last quarter. Hedge funds and other institutional investors own 69.66% of the company’s stock.
Kadmon stock traded down $0.02 during trading hours on Tuesday, hitting $3.34. The stock had a trading volume of 2,795,000 shares, compared to its average volume of 814,797. The company has a market capitalization of $400.38 million, a PE ratio of -2.38 and a beta of 3.46. Kadmon has a one year low of $2.86 and a one year high of $5.86.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Further Reading: Marijuana Stocks Investing Considerations
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.